Biogen Moves Alzheimer’s Drug to Late-Stage Trials. Wall Street Thinks It’s a Mistake.

Years after the launch of a controversial Alzheimer’s drug nearly crippled the company, Biogen is moving an experimental treatment into late-stage trials. Wall Street is not yet sold. Analyses showed diranersen slowed the progression of Alzheimer’s disease across all doses.